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Abstract
Multiple endocrine neoplasia type 1 (MEN1) syndrome is a rare hereditary cancer disorder characterized by tumors of the
parathyroids, of the neuroendocrine cells, of the gastro-entero-pancreatic tract, of the anterior pituitary, and by non-
endocrine neoplasms and lesions. MEN1 gene, a tumor suppressor gene, encodes menin protein. Loss of heterozygosity at
11q13 is typical of MEN1 tumors, in agreement with the Knudson’s two-hit hypothesis. In silico analysis with Target Scan,
Miranda and Pictar-Vert softwares for the prediction of miRNA targets indicated miR-24-1 as capable to bind to the 39UTR of
MEN1 mRNA. We investigated this possibility by analysis of miR-24-1 expression profiles in parathyroid adenomatous tissues
from MEN1 gene mutation carriers, in their sporadic non-MEN1 counterparts, and in normal parathyroid tissue. Interestingly,
the MEN1 tumorigenesis seems to be under the control of a ‘‘negative feedback loop’’ between miR-24-1 and menin
protein, that mimics the second hit of Knudson’s hypothesis and that could buffer the effect of the stochastic factors that
contribute to the onset and progression of this disease. Our data show an alternative way to MEN1 tumorigenesis and,
probably, to the ‘‘two-hit dogma’’. The functional significance of this regulatory mechanism in MEN1 tumorigenesis is also
the basis for opening future developments of RNA antagomir(s)-based strategies in the in vivo control of tumorigenesis in
MEN1 carriers.
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Introduction
MicroRNAs (miRNAs) are a family of naturally occurring,
evolutionary conserved, small (approximately 19–23 nucleotides),
non-protein-coding RNAs that negatively regulate post-transcrip-
tional gene expression. It is estimated that they account for .3%
of all human genes and control expression of thousands of
mRNAs, with multiple miRNAs targeting for a single mRNA [1].
Recent studies have also supported a role of miRNAs in the
initiation and progression of human malignancies [2], as altered
expression of miRNAs has been demonstrated in human tumors
such as colorectal neoplasia [3], B cell chronic lymphocytic
leukaemia [4,5], B cell lymphoma [6], lung cancer [7], breast
cancer [8], and glioblastoma [9,10]. The involvement of miRNAs
in human cancer is probably due to the fact that .50% of miRNA
genes are located at chromosomal regions, such as fragile or
common break point sites, and regions of deletion or amplification
that are generally involved in tumorigenesis [11].
Multiple Endocrine Neoplasia type 1 (MEN1) syndrome is a
rare complex tumor-predisposing disorder inherited in an
autosomal dominant manner [12]. MEN1 syndrome is character-
ized by tumors of the parathyroids, of the neuroendocrine cells, of
the gastro-entero-pancreatic tract, and of the anterior pituitary.
MEN1 gene, a tumour suppressor gene, whose translation product
is the menin protein, is characterized by loss of heterozygosity at
11q13 in MEN1 tumors [12].
In vitro menin recognizes its mRNA and a specific RNA-protein-
complex, also bound to MEN1 39-UTR mRNA [13]. This
suggests that the feedback oncosuppressor compensation by the
wild type menin in MEN1-mutated cells could be regulated
through RNA-protein-driven post-transcriptional mechanisms
[13].
A ribonucleoprotein structure, in which multiple mRNAs are
coordinately regulated by RNA binding proteins and by small
non-coding RNA (RNA regulons) could be hypothesized in the
menin-mRNA-miRNA(s)-transcription factors (Tfs) complex [14].
Several studies have demonstrated a central role of menin in the
regulation of gene transcription. This regulatory effect can be both
stimulatory and inhibitory [12]. Menin interacts with several
proteins involved in transcriptional regulation and RNA expres-
sion analyses have identified several menin-regulated genes that
could represent proximal or distal interaction sites for menin [15].
Tfs are essential regulators of gene expression, as they regulate
transcription of target genes by specifically binding to the
transcription factor binding site (TFBs) in gene promoter regions.
The expression of a miRNA may be regulated by TF/TFs and
miRNAs may regulate each other to form feed-back loops, or
alternatively, both TFs and miRNAs may regulate their target
genes and form feed-forward loops (FFLs) by creating a Gene
Regulatory Network (GRN) [16].
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softwares for the prediction of miRNA targets indicated miR-24-1
as capable to bind preferentially to the 39UTR of MEN1 mRNA,
and also to p27, p16, TGF-beta, and caspase 8, all involved in
MEN1 tumorigenesis. In this work, analysis of miR-24-1
expression profiles performed in parathyroid endocrine tissues
from MEN1 mutation carriers, in their sporadic non-MEN1
counterparts and in normal parathyroid tissue, showed that the
expression profiles of miR-24-1 mRNA and menin protein
generate a GRN.
Results
An Evolutionary Conserved Target Sequence for miR-24-
1 is Found in the 39UTR of MEN1 mRNA
The highly structured 832 nt-39UTR of MEN1 mRNA (Fig. 1A)
was screened for complementarity to seed sequences of known
miRNAs via a bioinformatic search by using TargetScan
prediction (release 6.0) software. A 7mer-m8 seed match was
found at nt 599–605 with a context score of 0.06 (Fig. 1B). This
miRNA site was conserved in Human, Mouse, Rat, Dog, and
Chicken (Fig. 1B). These data were confirmed by miRanda and
PicTar algorithms as well. The minimum free energy (mfe)
required for RNA hybridization is shown in Figure 1C. No
nucleotide variation in the MEN1 39UTR, that could affect the
miR-24-1 binding, was found at positions 599–605 nt in the
analyzed DNA samples.
miR-24-1 Acts Directly at the MEN1 39UTR
To confirm that miR-24-1 directly targets the highly-conserved
sequence identified in the 39UTR of MEN1 mRNA, a luciferase
reporter assay was performed. 29-O-methyl oligoribonucleotides
were characterized as sequence-specific inhibitors of miRNA
function and miRNA-direct RNA induced silencing complex
(RISC) activity [1]. These molecules stoichiometrically bind and
irreversibly inactivate miRNAs, providing a valuable tool to inhibit
the function of a single miRNA both in vitro and in vivo.
To evaluate the degree of miRNA inhibition, the inhibition of
miRNA-24-1 activity was verified by using pGL3/miR-24-1, a
luciferase expression plasmid containing the complementary miR-
24-1 binding sites. The luciferase expression plasmid containing
the complementary miR-24-1 binding site (pGL3/24), and an
analogous reporter with point substitutions disrupting the pairing
to the miRNA seed of miR-24 acting as a negative control (pGL3/
24MUT) were transfected in the human pancreatic neuroendo-
crine BON1 cells. The insertion of wild type sequences rendered
the reporter sensitive to endogenous miR-24-1, with a reduction in
luciferase activity when compared to the analogous mutated
reporter (Fig. 2A). Thus, the effect of cellular endogenous miR-24-
1 on translation of the luciferase mRNA was uniquely dependent
Figure 1. Putative miR-24-1 binding site on MEN1 39UTR mRNA. Panel A: Predicted secondary structure of MEN1 39UTR mRNA; Panel B: The
location of the putative miR-24-1 on MEN1 39UTR target site and the comparison of nucleotides between the miR-24-1 seed-sequence and its target
in four species are shown; Panel C: Predicted hybridization of miR-24-1 and MEN1 39-UTR by using RNAhybrid software. The minimum free energy
(mfe) required for RNA hybridization is shown.
doi:10.1371/journal.pone.0039767.g001
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39UTR, as expression of the luciferase reporter containing the
mutant miR-24-1 binding site within the 39UTR was unaffected
by the presence of endogenous cellular miR-24-1. Co-transfection
of the reporter plasmid with 29-O-methyl RNA antisense miR-24-1
(pGL3/24 wt+29-O-Me) enhanced the expression of the reporter
construct, indicating inhibition of endogenous miRNAs. By
contrast, co-transfection of the reporter plasmid with control
antisense RNA (pGL3/24+mut 29-O-Me) did not have the same
effect (Fig. 2A). This antisense-based-loss of function assay showed
inhibition of endogenous miR-24-1 at a functional level.
The effect of miR-24-1 antisense 29-O-methyl RNA and pre-
miR-24-1 treatment on endogenous miR-24-1 and menin protein
levels in BON1 cells was also determined. Pre-miR, the miRNA
precursor molecules, are small, chemically modified double-
stranded RNA molecules designed to mimic endogenous mature
miRNAs. After transfection of these RNA oligonucleotides in the
human pancreatic neuroendocrine BON1 cells, the endogenous
expression levels of miR-24-1, and menin were analyzed
respectively by Northern and by Western blot. Selective inhibition
of endogenous miR-24-1, by specific miR-24-1 antisense oligonu-
cleotides (Fig. 2B), induced an increase in menin expression (Fig-
2C) when compared to the miR-24-1 mutated antisense oligonu-
cleotides (Fig. 2B–C). Conversely, miR-24-1 reconstitution, by
transfection with pre-miR-24-1 (Fig. 2 B), induced a reduction of
menin expression (Fig. 2 C) due to the increased expression of
mature miR-24-1 (Fig. 2 B).
Figure 2. Luciferase assay and effects of miRNA inhibition/mimic. Panel A: WT reporter or mutated control luciferase plasmids were
transfected into BON1 cells alone or with 29-O-methyl miR-24-1 antisense RNA or 29-O-methyl miR24-1 mutated antisense RNA (negative control).
Reporter activities were measured after 2 days in differentiation media and normalized to Renilla luciferase activity. Bars indicate SD. *p,0.05 (paired
Student’s t-test, n=3) with respect to the control negative sample. Panel B: Northern blot of mature miR-24-1 showing the selective inhibition of
endogenous miR-24-,1 by specific miR-24 antisense RNA reported to the mutated antisense RNA as well as by the miR-24-1 overexpression with pre-
miR-24-1 compared to the negative pre-miR-C. Bars indicate SD. * Wt 24-1 29-O-Me vs Mut W24-1 29-O-Me (*p,0.05, paired Student’s t-test, n=3) and
# Pre-miR24-1 vs Pre-miR Control (*p,0.05, paired Student’s t-test, n=3). Panel C: Western blot analysis of menin expression performed to examine
the effect of miR-24-1 on menin expression in BON1 cells treated with both 29-O-methyl RNA and 29-O-methyl pre-miR-mimic. An average of three
experiments each performed in triplicate is presented. Bars indicate SD. *Wt 24-1 29-O-Me vs Mut W24-1 29-O-Me (*p,0.05, paired Student’s t-test,
n=3) and # Pre-miR24-1 vs Pre-miR Control (*p,0.05, paired Student’s t-test, n=3).
doi:10.1371/journal.pone.0039767.g002
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Expression in MEN1 Parathyroid Adenomatous Tissues
that Conserved the Wild-type Allele
If miR-24-1 was a negative tissue-specific regulator of the menin
oncosuppressor protein, then miR-24-1 should be over-expressed
in MEN1 parathyroid adenomatous tissues versus sporadic non-
MEN1 forms of parathyroid adenomas as well as in healthy
parathyroid tissue. Through the analysis of the different tissues for
LOH at both the MEN1 and miR-24-1 loci, four MEN1
parathyroid tumors showed LOH for the MEN1 allele (PA96,
PA83, P49, and PA22), while four parathyroid tumors (PH2,
PA86, PA62, and PA30) did not show MEN1-LOH, thus
preserving the MEN1 wild-type allele (Table 1). Both mutational
and LOH analyses of MEN1 allele in normal parathyroid and
sporadic adenoma tissues showed homozygous wild-type MEN1
allele. LOH analysis for miR-24-1 gene did not show any LOH in
any of the samples, as shown in Table 1. Northern blot analysis
was performed to analyze the expression level of miR-24-1 in
MEN1 parathyroid adenomas, in sporadic parathyroid adenomas
and in one normal parathyroid tissue. As shown in Figure 3A,
mature miR-24-1 was expressed only in MEN1 parathyroid
adenoma tissues that conserved the wild-type allele (without
MEN1-LOH), but not in the MEN1 parathyroid adenoma tissues
that lost the MEN1 gene (with MEN1-LOH), as well as in sporadic
parathyroid adenomas (Fig. 3 A). The different expression levels of
mature miR-24-1, consistent with results of the Northern blot
analysis, was confirmed by real-time qRT-PCR (Fig. 3B).
miR-24-1 is an Oncomir that Negatively Inhibits the
Oncosuppressor Menin Protein After the First ‘‘Hit’’
Those miRNAs whose expressions are increased in tumors may
be considered oncogenes. These oncogene miRNAs are known as
oncomirs and promote tumorigenesis by negatively inhibiting
tumour suppressor genes. Indeed, miRNAs regulate gene expres-
sion through decreased translation, increased degradation of the
target message, or both [4]. In order to check this hypothesis, we
analyzed both the expression of MEN1 mRNA and menin protein
in MEN1 and in sporadic parathyroid adenoma tissues. Real time
qRT-PCR analysis of MEN1 mRNA expression showed that in
MEN1 parathyroid adenomas that conserved one copy of the
MEN1 wild-type allele, there was around 50% reduction of MEN1
mRNA expression with respect to the control samples (normal
parathyroid tissue and sporadic adenomas with the homozygous
wild-type MEN1 allele), while expression of MEN1 mRNA was
strongly reduced in MEN1 parathyroid adenomas with LOH
where wild-type MEN1 gene was lost (Fig. 4A). Western blot in
lysates from both MEN1 parathyroid adenomas with MEN1-LOH
and without MEN1-LOH showed almost undetectable levels of
menin expression with respect to the sporadic forms and the
normal parathyroid tissue (Fig. 4B). These data are in agreement
with the absence of MEN1 mRNA expression of MEN1-LOH
parathyroid adenomas and high MEN1 mRNA expression levels
in the sporadic parathyroid adenomas and in normal parathyroid
tissue (Fig. 4A), but for the 50% expression level shown by MEN1
parathyroid adenomas that conserved one wild-type copy of
MEN1 gene (without MEN1-LOH), which should theoretically
express half of the menin protein (Fig. 4A). These findings could be
explained on the basis of a post-transcriptional negative control of
MEN1 mRNA function in the presence of over-expressed miR-24-
1 (Fig. 2A–B).
Negative Regulatory Loop between miR-24-1 and Menin
Exists in MEN1 Parathyroid Adenoma Tissues without
LOH
Because regulatory feedback loops between miRNAs and their
targets, mainly TFs, have been shown in several reports [17–19],
we hypothesized that the data reported above indicated the
possibility that, in MEN1 parathyroid adenoma tissues without
LOH, miR-24-1 and menin are linked by a negative regulatory
loop. To elucidate the transcriptional regulators involved in miR-
24-1 gene expression, we screened for transcriptional factor
binding sites in miR-24-1. Menin-binding sites in the promoter of
miR-24-1 were predicted by using the Transcription Element
Search Software program (http://www.cbil.upenn.edu/cgi-bin/
tess/tess), but we could not find any consensus menin binding sites.
That is because, although menin is proven to be a TF [12,15],
there are no data in the database used by prediction softwares. To
check this hypothesis, chromatin immunoprecipitation (ChIP)
assay for menin was performed using parathyroid tissues from
MEN1 patients. Co-precipitated DNA was analyzed by amplifying
the genomic region containing miR-24-1 promoter region by real
time PCR (Fig. 5). Occupancy of miR-24-1 promoter region was
observed only in MEN1 parathyroid adenoma tissues without
LOH (that conserved the wild-type copy of MEN1 allele), when
Table 1. Samples’ characteristics.
Pathology MEN1 mutation Tissue code LOH MEN1 (11q13) LOH miR24-1 (9q22.32)
Normal parathyroid gland NO P3 NO NO
Parathyroid adenoma (NON MEN1) NO PA2 NO NO
Parathyroid adenoma (NON MEN1) NO PA57 NO NO
Parathyroid adenoma (NON MEN1) NO PA93 NO NO
Parathyroid hyperplasia (MEN1) Frameshift, 1555insG, exon 10 PH2 NO NO
Parathyroid adenoma (MEN1) Frameshift, 953delGA, exon 6 PA30 NO NO
Parathyroid adenoma (MEN1) Frameshift, 317ins5(GCCCC), exon 2 PA62 NO NO
Parathyroid adenoma (MEN1) Frameshift, 359del4 (GTCT), exon 2 PA86 NO NO
Parathyroid adenoma (MEN1) Nonsense, Gln508Stop, exon 10 PA22 YES NO
Parathyroid adenoma (MEN1) Frameshift, 335delA, exon 2 PA49 YES NO
Parathyroid adenoma (MEN1) Nonsense, Gln508stop, exon 10 PA83 YES NO
Parathyroid adenoma (MEN1) Splicing 765-1(AG.AA), intron3-exon 4 PA96 YES NO
doi:10.1371/journal.pone.0039767.t001
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to control IgG (Fig. 5). These results indicate that menin occupies
the miR-24-1 gene promoter, thus inducing its expression. As
menin is a positive regulator of miR-24-1, while miR-24-1
negatively regulates the expression of menin, we conclude that
menin and miR-24-1 form a ‘‘negative feedback loop’’ in the
MEN1 parathyroid adenoma tissues without LOH (which thus still
have one copy of the wild type allele).
Discussion
In this study, we showed that in MEN1 syndrome, a rare
complex tumor-predisposing disorder inherited in an autosomal
dominant manner, the onset and progression of disease, after the
first inherited ‘‘hit’’ is under the control of a ‘‘negative feedback
loop’’ between menin and miR-24-1. This mechanism mimics the
second somatic ‘‘hit’’ of tumor suppressor inactivation, thus
indicating a potential mechanism for tissue-selective tumorigenesis
in this hereditary tumor syndrome. Indeed, the main question
regarding the pathogenetic basis of MEN1 syndrome is its
predominant endocrine tumoral phenotype, with variable clinical
manifestations not-related to the type of MEN1 gene inactivating
mutations. Candidate tissue-specific regulators may include
miRNAs and TFs. We previously showed that in primary cultures
of fibroblasts from MEN1 patients wild type MEN1 gene allele-
encoded mRNAs were expressed, whereas mutant alleles were
partially degraded by a nonsense-mediated mRNA decay (NMD)
pathway, suggesting a mechanism of feedback compensation for
allelic loss by the up-regulation of wild-type menin expression at
post-transcriptional level [13]. We also showed that menin forms a
ribonucleoprotein structure in which multiple mRNAs should be
coordinately regulated by RNA binding proteins and miRNAs
[13]. This mechanism could be a way to control the haploinsuffi-
ciency that occurs when one allele is insufficient to confer the full
functionality produced from two wild-type alleles.
In the present study, we analyzed the expression profile of miR-
24-1 in parathyroid adenomas from MEN1 patients, with different
MEN1 mutations, in which the main difference was the MEN1
LOH or the maintenance of the wild type MEN1 allele. Analysis
of miR-24-1 LOH showed no LOH for all the analyzed samples.
While parathyroid adenomas from patients that lost both MEN1
alleles showed no expression of MEN1 mRNA, of menin, or of
miR-24-1, MEN1 parathyroid adenomas from patients that
maintain one wild type copy of the MEN1 gene showed, as
Figure 3. Expression analysis of mature miR-24-1 in parathyroid samples. Panel A: Northern blot analysis of mature miR-24-1 in normal
parathyroid tissue, in MEN1 parathyroid adenomas and in non-MEN1 parathyroid adenomas; and panel B: Real time quantitative RT-PCR analysis of
mature miR-24-1 in normal parathyroid tissue, MEN1 parathyroid adenomas, and non-MEN1 parathyroid adenomas. Bars indicate SD. An average of
three experiments each performed in triplicate.* # p,0.05 (paired Student’s t-test, n=3)with respect to the control sample, the normal parathyroid
tissue.
doi:10.1371/journal.pone.0039767.g003
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expression of menin, while miR-24-1 was expressed. Thus, the
induction of miR-24-1 seems to depend on transcriptional
expression of MEN1 mRNA. The ChIP study demonstrated the
association of menin with the miR-24-1 promoter, suggesting that
the pri-miR-24-1 transcription was regulated by menin. The same
mechanism does not seem to be involved in the sporadic
parathyroid adenomas which usually occur later in the life of
patients.
We showed that menin is the target of one miRNA, the
miR-24-1, that directly targets the highly-conserved sequence
identified in the 39UTR of MEN1 mRNA, thus offering an answer
to the endocrine tissue-specificity of MEN1 tumors. Results from
this study suggested that in MEN1 syndrome, after the first
inherited germinal ‘‘hit’’, the somatic onset and progression of
neoplasia could be under the control of a ‘‘negative feedback loop’’
between menin protein and miR-24-1. We hypothesized that this
regulatory network could mimic and substitute the second somatic
‘‘hit’’ of tumor suppressor inactivation in tissues in which MEN1
LOH has not yet occurred or could represent an intermediate step
before the MEN1 LOH (Fig. 6). This mechanism should explain
the proliferative changes in the neuroendocrine cells that could
precede neoplasia. In the duodenum and the pancreas, the MEN1
gene-associated germline mutation causes hyperplasia of gastrin,
somatostatin and glucagon-secreting cells, resulting in multifocal
development of tumors [20]. Indeed, these tumors show allelic
deletion of the MEN1 gene, whereas the precursor lesions retain
their heterozygosity [20]. In MEN1 the mechanism leading to
neuroendocrine hyperplasia could be explained by the proposed
‘‘negative feedback loop’’ between menin and miR-24-1 acting as
‘‘homeostatic regulatory network’’ that need to be ‘‘broken’’ to
induce the somatic ‘‘hit’’ and, consequently, to the neoplasia.
Many human genetic diseases result from loss-of-function germ-
line mutations in one of the two homologous gene loci. These are
often referred to as autosomal dominant diseases because of
frequent phenotypic dominance of the mutated allele over the wild
type allele during transmission along generations. There is
presently one prevailing theory explaining the autosomal domi-
nant expression of these diseases. This explanation originates from
the Knudson two-hit theory of hereditary cancers, where loss of
Figure 4. Expression analysis of menin protein and MEN1 mRNA. Panel A: Real time quantitative RT-PCR analysis of MEN1 mRNA in normal
parathyroid tissue, in MEN1 parathyroid adenomas, and in non-MEN1 parathyroid adenomas. An average of three experiments each performed in
triplicate; and panel B: Densitometric Western blot analysis (NIH-Image) in normal parathyroid tissue, in MEN1 parathyroid adenomas and in non-
MEN1 parathyroid adenomas. Density ratio menin/beta-actin: bar diagram. Bars indicate SD. * # p,0.05 (paired Student’s t-test, n=3) with respect to
the control sample, the normal parathyroid tissue.
doi:10.1371/journal.pone.0039767.g004
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function of the wild-type copy [21–24]. While this somatic second
hit may be sufficient for stable disease states, it is often difficult to
determine if their occurrence necessarily marks the initiation of
disease progression [25,26]. Stochastic factors are likely to
contribute to the characteristics of variable time of onset and
incomplete penetrance of many autosomal dominant diseases
[27,28]. GRNs involving positive and negative feedbacks could
control the effects of noise, by buffering its impact on gene
expression [29]. In GNRs, TFs and miRNAs may reciprocally
regulate one another to form ‘‘feedback loops’’, or alternatively,
both TFs and miRNA may regulate their target genes and form
‘‘feed-forward loops’’ [29]. Feedback loops are network structures
that appear to have two functions in biological systems: they act as
rapid switches to turn on a process [30,31] and they act as noise
buffers to enable a system to respond to long term signal changes
[31]. Particularly, ‘‘negative feedback loops’’ potentially function
to fine-tune gene expression and to maintain precise steady state
levels of both components of the loop [29] and can result in
oscillatory expression of both components, which depends on
additional input signals [32]. We could hypothesize that the
‘‘negative feedback loop’’ between menin and miR-24-1 works
buffering external and/or internal influences, as hormones and/or
environmental factors. Epigenetic perturbations of this system
could indeed drive the MEN1 tumorigenesis, as also supported by
the individual clinical manifestation in MEN1 patients, indepen-
dent on the type of MEN1 gene mutation.
In conclusion, we showed that MEN1 syndrome could originate
from mechanisms alternative to LOH. These events are under the
control of a GRN, where miRNA-24-1 represents a strategic target
to develop a therapeutic silencing antagomir to control MEN1
tumorigenesis progression [33].
Materials and Methods
Tissues Collection
We collected specimens from patients who underwent surgical
parathyroid excision for benign adenomas; in particular we have
obtained parathyroid tissues from MEN1 patients, exhibiting
different MEN1 gene mutations, as well as sporadic parathyroid
adenoma samples from non-MEN1 patients (Table 1). Normal
human parathyroid tissue used as healthy control was obtained by
patients operated for thyroid carcinoma and pooled from three
different cases. The data were analyzed anonymously and we used
tissues collected before the establishment of ‘‘AOUC Ethics
Committee’’.
Cell Cultures
Human pancreatic neuroendocrine BON1 tumour cells were
kindly provided by Dr. Auernhammer (Munich, Germany). BON1
cells were cultured in DMEM/F12 (1:) medium (Life Technolo-
gies, Invitrogen, Foster City, CA USA) supplemented with 10%
FCS., 1% penicillin/streptomycin (Life Technologies, Invitrogen),
and 0,4% amphotericin (Biochrom, Cambridge, UK) in a 5%
CO2 atmosphere.
MEN1 Gene Mutational Analysis
Genomic DNA of the MEN1 patients was extracted from
peripheral blood leukocytes using a microvolume silica mem-
brane-based column system according to the manufacture’s
instructions (NucleoSpin Blood Quick Pure; Macherey-Nagel,
Easton, PA, USA). Mutational analysis of the encoding regions
(exons 2–10) and of the intron-exon junctions of the MEN1 gene
was performed by PCR-based direct sequencing.
Loss of Heterozygosity Analysis
PCR-based microsatellite analysis for Loss of Heterozigosity
(LOH) in the MEN1 region was performed in parathyroid tissue
DNA samples versus blood DNA samples. LOH analysis was
Figure 5. Chromatin immunoprecipitation analysis (ChIP). Chromatin extracts were prepared from a MEN1 parathyroid adenoma without
LOH and a MEN1 parathyroid adenomas with LOH. Chromatin was immunoprecipitated with anti-menin antibody, or with IgG antibody as negative
control. Quantitative SYBR green PCR was performed to determine whether the miR-24-1 promoter was present in the immunoprecipitate. Bars
indicate SD. *p,0.05 (paired Student’s t-test, n=3) with respect to the control sample.
doi:10.1371/journal.pone.0039767.g005
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PYGM, D11S449, and D11S913) flanking the 11q12-13 locus.
PCR-based microsatellite analysis for LOH in the 9q22.32 region,
containing the human miR-24-1 gene, was performed in genomic
DNA from parathyroid tissues versus blood-derived genomic
DNA. LOH analysis was performed using 4 specific microsatellite
markers (D9S167, D9S278, D9S283, D9S280) flanking the
9q22.32 locus. An independent PCR amplification was performed
for each microsatellite in a final volume of 12.5 ml using PuReTaq
Ready-To-Go PCR beads (GE Healthcare, Buckinghamshire,
UK). An aliquot of each amplification product was denatured at
95uC for 5 min, in a solution of formamide and GENESCAN
400HD [ROX] size standard (Applied Biosystems), and then
analyzed on the ABI Prism 3100 Genetic Analyzer (Applied
Biosystems) by GenescanHanalysis software.
MicroRNA Target Prediction
The candidate targets of miR24-1 were identified based on a
conservative intersection of the following microRNAs target
prediction tools: TargetScan (http://genes.mit.edu/targetscan),
Miranda (http://www.microrna.org/), and Pictar (http://pictar.
bio.nyu.edu/). The minimum free energy required for RNA
hybridization was predicted by using RNAhybrid software (http://
bibiserv.techfak.uni-bielefeld.de/).
MEN1 39UTR Region Sequencing
The 39UTR of the MEN1 gene was analyzed, in blood-derived
genomic DNA from all the subjects included in this study, by
PCR-based direct and reverse sequencing for the screening of
possible polymorphic variants, in the two binding sites to miR-24-
1 evidenced by prediction tools (position 59–65 of MEN1 39UTR
and position 599–605 of MEN1 39UTR), that could affect the
miR-24-1-MEN1 mRNA bound.
Oligoribonucleotides, Reporter Plasmids and Luciferase
Assays
29-O-methyl oligoribonucleotides miR-24-1 antisense, 59-CU-
GUUCCUGCUGAACUGAGCC-39; miR-24-1 antisense mutat-
ed, 59-CUGUUCCUGCUGAACUGCUUU-39) were synthesized
by IBA (Gottingen, Germany). Reporter constructs that contain a
miR-24-1 binding site (‘‘pGL3-24-1’’) or a mismatch sequence
(‘‘pGL3-24-1MUT’’) in the 39UTR of MEN1 mRNA were
constructed by amplification of the full-length 39UTR MEN1
(832 nt) using the following primers: 59-CAGAGATC-
TAAGTCGTGTGAAATCATGTG-39 (FW), 59-TAAGTCGA-
CAACAGGGTTTTCCAAGTCTA-39 (RV) cloned into the
Xba1-site of pGL3 (Promega, Madison, WI, USA), checked for
orientation, sequenced and named.
Two hundred ng of Reporter or control plasmid (plus 80 ng
pRL-null; Promega; Madison, WI, USA) were transfected, alone
Figure 6. miR-24-1 menin Gene Regulatory Network. Panel A: Menin transcription activation regulates the transcription rate of miRNA 24-1
that repress post-transcriptionally menin. Panel B: Menin inactivation via ‘‘two hits’’. The first ‘‘hit’’ is acquired in the germline with the second ‘‘hit’’
being acquired somatically.
doi:10.1371/journal.pone.0039767.g006
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tides, in the BON1 cells, using Lipofectamine (Invitrogen).
Luciferase assays were performed 48 h after transfection using
the Dual Luciferase Reporter Assay System (Promega). Firefly
luciferase activity was normalized to renilla luciferase activity for
each transfected well. Each transfected well was assayed in
triplicate.
Transient Transfections
For the transfection experiments, a miR-24-1 precursor (pre
miR-24-1) and a Pre-miR negative control (pre C; random
sequence Pre-miR molecules extensively tested in human cell lines
and tissues and validated to do not produce identifiable effects on
known miRNAs function) were obtained by Ambion (Applied
Biosystems). 29-O-Me antisense miR-24-1 and miR-24-1 antisense
mutated were described above. BON1 cells were transfected with
RNAs (200 pmol) by using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Cells were harvested
48 h after initial transfection and proteins and RNAs were isolated
by using ‘‘PARIS’’ (Ambion).
Northern Blot Analysis
Total RNA was isolated with Trizol reagent (Invitrogen)
according to the manufacturer’s instructions. For miRNA
Northern blots, 15 mg of total RNA were separated on 15%
denaturing polyacrylamide gels, electro-transferred to GeneScreen
Plus membranes (PerkinElmer, Waltham, MA, USA), and
hybridized using UltraHyb-Oligo buffer (Applied Biosystems) at
42uC overnight. Oligonucleotides, complementary to mature
miRNAs, were
32P end-labeled with T4 Kinase (Roche Diagnos-
tics, Indianapolis, IN, USA) and were used as probes. Probe
sequences were: 59-CTGTTCCTGCTGAACTGAGCCA-39 as
miR-24-1 antisense, and 59-TTAGCTTCCGAGATCAGAC-
GATTTTTCCTGTCTC-39 as 5S antisense.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was used to detect
protein-DNA interactions. Tissues ChIP analysis was performed
with a commercially available EpiQuik Tissue Chromatin
Immunoprecipitation (ChIP) Kit in accordance with the manu-
facturer’s instructions. The chromatin fraction was immunopre-
cipitated overnight at 4uC using anti-menin (BL342) polyclonal
antibody (Bethyl, Montgomery, TX, USA) and anti-IgG antibod-
ies, followed by stringent washing and elution. Quantitative PCR
amplification analysis was performed in a total volume of 25 ul
with specific primers. The forward and reverse primers used for
each gene were as it follows:
59-AGCAGCTAGCAGGGTGATGT-39;5 9-CATGGGAA-
GAACAGAGGATGA-39.
Quantitative Real-time PCR
Real-time RT-PCR was carried out as it follows. The
experiment was replicated on two different cell samples. Ten mg
of total RNA from each sample were DNAse treated with DNA-
free kit (Ambion). Two ml of diluted RNA were reverse transcribed
by using miScript reverse transcription Kit (Quiagen, Germany)
and amplified using miScript SYBR Green PCR Kit and miR-24-
1 and 5S miScript Primer assay (Quiagen) and MEN1 and 18S
RNA Quantitec primer assay. Each RNA sample was evaluated
for transcript levels in triplicate (including the normalization
control 5S/18S) and quantified with MX3000P multiplex
quantitative PCR instrument (Stratagene, La Jolla, CA, USA)
following a unique three-step protocol: one cycle at 95u for 15 min
and 40 amplification cycles (94uC for 15 sec, 1 min at 55uC and
70uC for 30 sec). Sample fluorescence was detected during the
annealing step. The fluorescence data were collected continuously
to obtain the dissociation curve. Fluorescence was plotted versus the
Ct (threshold cycle) based on dRn (baseline-corrected, reference
dye-normalized fluorescence) to obtain the standard curve and to
measure the initial template quantity. Gene expression was
normalized to 5S RNA or 18S RNA. Fluorescence data were
analysed using MXPro Software.
Western Blotting
Cell and tissue lysates were prepared by the PARIS purification
kit. Protein concentrations were determined by the BCA protein
assay (Pierce, Rockford, IL, USA) using bovine serum albumin as
the standard protein. Fifteen mg of each cell protein extract were
denatured 10 minutes at 95uC in a volume of 95% Laemmli
Sample Buffer (Bio-Rad, Hercules, CA, USA) and 5% beta-
mercaptoethanol solution. Proteins were separated by SDS-12%
polyacrylamide gel electrophoresis. The separated protein bands
were transferred electrophoretically to a nitrocellulose membrane
(Optitran BA-S 83, Schleicher & Schuell, Dassel, Germany) for 1
hour in a Mini Trans-blot electrophoretic transfer cell (Bio-Rad) at
100 V. Filters were blocked for 1 hour at room temperature in a
blocking solution of PBS, 0.1% tween 20 and 2% ECL Advance
blocking agent (Amersham Biosciences, Little Chalfont, UK). To
evaluate menin expression, the blocked membrane was incubated
with rabbit anti-menin (BL342) polyclonal antibody (Bethyl) for 1
hour at room temperature (1:1000 dilution of stock in blocking
solution), washed 4 times for 5 minutes each with a solution of PBS
and 1% tween 20, incubated with an antirabbit horseradish
peroxidase-conjugated secondary antibody (Santa Cruz, CA,
USA) for 1 hour at room temperature (1:2000 dilution of stock
in blocking solution), then washed 4 times for 5 minutes each with
a solution of PBS and 1% tween 20 and finally washed once with
PBS. Detections of membrane-bound anti-menin antibody were
performed by chemiluminescence. Beta-actin was used as a
housekeeping protein.
Statistical Analysis
Data are expressed as mean 6 SD. All blots represent at least
three separate experiments. Data shown were done in triplicate for
each experiment, and are representative of three or more
experiments. Comparisons were made by using a two-tailed t test
or one-way ANOVA for experiments with more than two
subgroups. Probability values were considered statistically signif-
icant at p,0.05. Due to the rarity of MEN1 syndrome, the
current parathyroid sample size is relatively small, thus
the potency of the current statistical analysis could be
reduced.
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